Menu
Oslo, 5 May 2026: Reference is made to the stock exchange announcement made by Thor Medical ASA (the "Company") on 2 May 2025 regarding grant of restricted share units ("RSU") to the members of the board as part of their board remuneration under the RSU-program.
The Company's board of directors has today resolved to issue 219,521 new shares in the Company pursuant to the RSU-program, in accordance with the board remuneration approved by the Company's annual general meeting in 2025. In connection therewith, the following board members have been issued new shares:
Jens Gisle Schnelle has transferred 164,641 shares to his personal holding company, Exman AS, a close associate of a primary insider of the Company.
Further, reference is made to the stock exchange announcement made by the Company on 23 April 2026 and that the annual general meeting approved the remuneration to the Company's board of directors. The board members were given the choice to receive their remuneration, or a part thereof, for the period between the annual general meeting in 2026 and 2027 in the form of RSUs, as a part of the Company's RSU program. The allocation of RSUs has today been made.
The number of RSUs allocated to each board member has been determined based on the NOK value for the RSU-selected portion of the total compensation for the board member. The compensation is divided by the market price of NOK 5,177, equal to the 10-day volume weighted average prior the annual general meeting on 23 April 2026. A total of 108,170 RSUs has been allocated to the following board members:
Notifications of the transaction in accordance with the Market Abuse Regulation Article 19 are attached with this announcement.
CONTACTS
* Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05 724, mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium, a key component of next-generation targeted cancer treatment. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides a reliable, environmentally friendly and cost-efficient supply of alpha emitters to the radiopharmaceutical industry. Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by fueling next-generation cancer therapies with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com.
This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Securities Trading Act.
